Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.

Oncology (Williston Park, N.Y.)

Volumn 17, Issue 5 Suppl 5, 2003, Pages 15-24

  Milas, Luka ^a   Mason, Kathryn A ^a   Crane, Christopher H ^a   Liao, Zhongxing ^a   Masferrer, Jaime ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG DERIVATIVE; IRINOTECAN; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANIMAL; CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION EXPOSURE; RADIOTHERAPY; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RADIOTHERAPY;

EID: 0141783810     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)